After the UK-based parent of GSK Pharma announced an open offer proposing to buy nearly 25% of the firm at a price of Rs 3,100 per share – a nearly 26% premium to the stock‘s Friday closing price, CNBC-TV18 spoke with Ranjit Kapadia, Pharma Analyst, Centrum Broking, to get his view.
first published: Dec 16, 2013 10:57 am
A collection of the most-viewed Moneycontrol videos.
SOBO to Bandra: Why Only South Mumbai Residents Call Bandra a Downgrade | The Tenant
Live: Nifty registers third straight week of gains, up 2% in November | Closing Bell
Live: Can Nifty continue to step up its move to fresh peaks? | Opening Bell
Live: Sensex, Nifty retreat after mounting on new lifetime highs | Closing Bell
